TerminatedPhase 4

Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke

Stopped: Intended length of study ended

Switzerland16 participantsStarted 2001-01

Plain-language summary

The aim of the study is to evaluate the effect of Dextro-amphetamin added to physiotherapy on motor recovery in patients after stroke. The study is a double-blinded placebo-controlled randomised controlled trial. Patients after a first-ever ischemic stroke will receive Dexamphetamine (10mg) twice per week for a duration of five weeks after a baseline phase of two weeks. The outcome measure focuses on motor recovery and will be assessed: * one and two weeks before study intervention (baseline phase) * five times during the study intervention * one week after study intervention (follow-up) * once after six and twelve months after start of the study intervention (follow-up).

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients after first-ever ischemic stroke with a clinical relevant paresis of the upper and lower limb (general clinical muscle testing below level four) * correlation of clinical symptoms with a brain imaging (CT or MRI) * able to communicate with the neurological examiner and understand the aim/matter of the study (with or without aphasia) * start of the first oral application of the study drug between the fourteenth and 60th day after stroke onset * older than 13 years * given written informed consent (or two independent witnesses) Exclusion Criteria: * intracranial or (chronic) subdural hemorrhages * any additional neurological or psychiatric illnesses * instable arrythmia * not controlled or treated arterial hypertension * ensured cardioembolic event * anxiolytica, neuroleptica, or alpha-adrenergic antagonists or agonists respectively * certain anticonvulsiva or antihypertonica * manifest hyperthyreosis * dementia or terminal illnesses * epilepsy, phaeochromocytoma or glaucoma * women known to be pregnant or lactating

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Chedoke-McMaster Stroke Assessment (motor impairment measure)

Timeframe: Over the whole duration of the study (2001 to 2006, ten times for each patient)

Trial details

NCT IDNCT00572767

SponsorReha Rheinfelden

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Stroke trials